BL-B01D1 Clinical Trials
33 recruitingDrug
Phase 222Phase 38Phase 15
Showing 1–20 of 33 trials
Recruiting
Phase 3
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.538 enrolled1 locationNCT07582315
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Triple-Negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.52 enrolled1 locationNCT06471205
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Non-small Cell Lung CancerSolid TumorNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.570 enrolled1 locationNCT06475300
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.66 enrolled1 locationNCT06437509
Recruiting
Phase 2
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.46 enrolled1 locationNCT06437522
Recruiting
Phase 2
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.52 enrolled1 locationNCT06405425
Recruiting
Phase 3
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.446 enrolled1 locationNCT07648914
Recruiting
Phase 2Phase 3
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Esophageal Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.90 enrolled1 locationNCT07554456
Recruiting
Phase 3
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.450 enrolled1 locationNCT06994195
Recruiting
Phase 2
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.74 enrolled1 locationNCT06986785
Recruiting
Phase 3
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.720 enrolled1 locationNCT06838273
Recruiting
Phase 3
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)
Urothelial Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.508 enrolled1 locationNCT06857175
Recruiting
Phase 1
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Breast CancerTriple-Negative Breast CancerEsophageal Cancer+9 more
SystImmune Inc.470 enrolled39 locationsNCT05983432
Recruiting
Phase 2
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Cervical CancerEndometrial Cancer
Sichuan Baili Pharmaceutical Co., Ltd.96 enrolled1 locationNCT07054567
Recruiting
Phase 2
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.260 enrolled1 locationNCT06962787
Recruiting
Phase 2
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Head and Neck Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.186 enrolled1 locationNCT06006169
Recruiting
Phase 2
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Non-small Cell Lung CancerNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.121 enrolled16 locationsNCT05956587
Recruiting
Phase 1
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
Gastrointestinal Tumor
Sichuan Baili Pharmaceutical Co., Ltd.96 enrolled6 locationsNCT05262491
Recruiting
Phase 2
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.58 enrolled1 locationNCT06042894
Recruiting
Phase 1Phase 2
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Solid TumorGynecological Malignant Tumor
Sichuan Baili Pharmaceutical Co., Ltd.38 enrolled1 locationNCT05803018